Entero Healthcare Solutions Limited has informed the Exchange about Transcript
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Entero Healthcare reported a strong start to FY26, with Q1 revenue of Rs. 1,404 crores growing 28% year-on-year (31% on a like-to-like basis), significantly outpacing the Indian pharma market growth of 9%. Like-to-like growth was 15% organic (about 1.6x the market) plus 16% inorganic, with 3% shaved off due to a change in revenue recognition for one client contract. EBITDA rose 66% YoY to Rs. 50 crores with margins of 3.6% (up 82 bps YoY but down 10 bps QoQ due to annual salary hikes baked into Q1). Profit after tax grew 47% to Rs. 30 crores. Management maintained full-year guidance of 30%+ revenue growth, 4%+ EBITDA margins, and positive operating cash flow. Net working capital days improved to around 66 (from 71 a year ago), with a target of 60 days by year-end. The company has Rs. 365 crores of cash on books, plans to add ~Rs. 500 crores of inorganic revenue, and has 4 acquisitions in the pipeline (2 already closed).
Shareholders can view this as a positive update: growth is running well ahead of industry, the margin dip is one-off (salary cost), and management has clear levers (operating leverage, procurement, working capital) to deliver the 4%+ EBITDA margin guidance. Sequential margin compression and dependence on M&A for a portion of growth remain near-term watchpoints.